Exhibit 99.1



Tetraphase Pharmaceuticals Reports Fourth-Quarter and Full-Year 2015 Financial Results and

Provides Corporate Update

– Company to host conference call at 4:30 p.m. ET today –

WATERTOWN, Mass., February 23, 2016 –

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the fourth quarter and year ended December 31, 2015 and provided a review of corporate milestones for 2016.

“We are focused on continuing to advance the development of eravacycline as we remain confident in its potential to become an important option for patients with serious infections,” said Guy Macdonald, Tetraphase’s President and Chief Executive Officer. “We continue to have discussions with the FDA regarding the next steps for IV eravacycline and look forward to providing an update after we have received regulatory guidance, which we still anticipate in the first quarter of 2016.”

“In parallel, we are planning to initiate an additional phase 3 clinical trial for once-daily IV eravacycline in complicated urinary tract infections (cUTI) in the third quarter of 2016, the design for which is currently being finalized. We are also continuing the clinical development of an oral dose formulation for eravacycline,” Mr. Macdonald added. “Beyond the eravacycline program, we are advancing our pipeline of novel antibiotic candidates. We will continue our phase 1 clinical program for TP-271 which is being developed to combat respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens. We also plan to initiate a phase 1 clinical trial evaluating TP-6076, our second-generation antibiotic candidate with potent activity against multidrug-resistant Gram-negative pathogens, during the second quarter of 2016. We look forward to keeping you updated on our progress throughout the year.”

Key Milestones for 2016


    Provide regulatory update on eravacycline program – 1Q 2016


    Initiate IV-only phase 3 clinical trial for eravacycline in cUTI - 3Q 2016


    Initiate new clinical studies to advance the oral eravacycline development program - 2Q 2016


    Advance TP-271 phase 1 clinical program - 2016


    Initiate phase 1 clinical trial for TP-6076 - 2Q 2016


    Present scientific data from antibiotic candidates at scientific meetings - 2016

Fourth-Quarter and Full-Year 2015 Financial Results

As of December 31, 2015, Tetraphase had cash and cash equivalents of $205.9 million and 36.6 million shares outstanding. The company expects that its cash and cash equivalents, as well as expected revenue from its U.S. government awards, will be sufficient to fund operations into at least early 2018.

The following information was filed by Tetraphase Pharmaceuticals Inc (TTPH) on Tuesday, February 23, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Tetraphase Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Tetraphase Pharmaceuticals Inc.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account